HC Wainwright Issues Positive Forecast for ETON Earnings

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) – Equities researchers at HC Wainwright raised their Q2 2025 earnings per share (EPS) estimates for shares of Eton Pharmaceuticals in a research report issued on Monday, January 6th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of $0.08 per share for the quarter, up from their prior forecast of $0.07. HC Wainwright has a “Buy” rating and a $17.00 price target on the stock. The consensus estimate for Eton Pharmaceuticals’ current full-year earnings is ($0.17) per share. HC Wainwright also issued estimates for Eton Pharmaceuticals’ FY2025 earnings at $0.38 EPS and FY2026 earnings at $0.84 EPS.

Several other equities analysts have also recently issued reports on ETON. Craig Hallum boosted their price target on shares of Eton Pharmaceuticals from $15.00 to $18.00 and gave the company a “buy” rating in a research report on Wednesday. B. Riley started coverage on Eton Pharmaceuticals in a research report on Friday. They set a “buy” rating and a $21.00 price objective for the company.

Eton Pharmaceuticals Stock Up 11.9 %

NASDAQ:ETON opened at $13.44 on Thursday. The company has a fifty day moving average of $11.64 and a 200 day moving average of $7.35. Eton Pharmaceuticals has a 52 week low of $3.03 and a 52 week high of $15.00. The firm has a market capitalization of $350.13 million, a P/E ratio of -61.09 and a beta of 1.38.

Hedge Funds Weigh In On Eton Pharmaceuticals

Several institutional investors have recently bought and sold shares of ETON. Point72 Asia Singapore Pte. Ltd. bought a new position in Eton Pharmaceuticals during the third quarter valued at $54,000. Jane Street Group LLC bought a new stake in shares of Eton Pharmaceuticals during the 3rd quarter worth approximately $90,000. Renaissance Technologies LLC boosted its holdings in Eton Pharmaceuticals by 63.8% during the 2nd quarter. Renaissance Technologies LLC now owns 106,500 shares of the company’s stock valued at $350,000 after acquiring an additional 41,469 shares during the period. Stonepine Capital Management LLC bought a new position in Eton Pharmaceuticals in the 2nd quarter valued at $362,000. Finally, Connor Clark & Lunn Investment Management Ltd. increased its stake in Eton Pharmaceuticals by 86.6% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 65,014 shares of the company’s stock worth $390,000 after purchasing an additional 30,167 shares during the period. 27.86% of the stock is owned by hedge funds and other institutional investors.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.